Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

OLOlivia LiuUniversity of KentuckyOOOlatoyosi OdenikeUniversity of ChicagoJDJeanne M. DeCaraUniversity of Chicago

Discussion

Loading...

Member takes

Overview

Analysis reveals low cholesterol is linked to worse clinical outcomes in myeloproliferative neoplasms, suggesting implications for cardiovascular disease management.

Key Points

  • Investigate the association between serum total cholesterol and clinical outcomes in patients with myeloproliferative neoplasms.
  • Retrospective analysis of MPN patients with transthoracic echocardiogram data
  • Comparison of patients with total cholesterol below and above median levels
  • Assessment of hematologic and cardiovascular outcomes
  • Utilization of multivariable competing-risk regression and Cox proportional hazards modeling
  • 305 patients analyzed, including 118 with polycythemia vera, 100 with essential thrombocythemia, and 87 with myelofibrosis.
  • Lower cholesterol levels associated with higher risk of hematologic progression and heart failure hospitalization.
  • Adjusted hazard ratios indicated significantly increased risk for all-cause mortality in patients with low cholesterol levels.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d479https://doi.org/10.1182/blood-2025-2020
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms2026 · 5 citations
  2. 2Blood Cholesterol and Outcome of Patients with Cancer under Regular Cardiological Surveillance2021 · 6 citations
  3. 3Peripheral blood plasma proteomics reveals dysregulated cholesterol transport and complement pathways in myeloproliferative neoplasms2025
  4. 4Association of elevated pulmonary artery systolic pressure with hematologic progression in myeloproliferative neoplasms.2024 · 1 citations
  5. 5Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis2026